• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对接受成功治疗的HIV感染者(PLWHs)的乙肝疫苗免疫反应:一项前瞻性队列研究。

Immune Responses to HBV Vaccine in People Living with HIV (PLWHs) Who Achieved Successful Treatment: A Prospective Cohort Study.

作者信息

Xu Ling, Zhang Li, Kang Shuang, Li Xiaodi, Lu Lianfeng, Liu Xiaosheng, Song Xiaojing, Li Yanling, Li Xiaoxia, Lyu Wei, Cao Wei, Liu Zhengyin, Li Taisheng

机构信息

Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

Center for AIDS Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

出版信息

Vaccines (Basel). 2023 Feb 9;11(2):400. doi: 10.3390/vaccines11020400.

DOI:10.3390/vaccines11020400
PMID:36851279
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9967144/
Abstract

BACKGROUND

Understanding immune responses after HBV vaccination is important to prevent HBV infection in PLWH and to achieve successful treatment.

METHODS

Thirty-two PLWHs with CD4 cell count > 350 cells/µL and HIV RNA < 200 copies/mL were vaccinated with 20 µg of HBV vaccine at weeks 0, 4, and 24 in this prospective study. We measured total HIV DNA levels, HBsAb titers and HBsAg-specific T-cell responses during follow-up time.

RESULTS

All patients achieved protective HBsAb titer after immunization. The magnitude of the IFN-r and TNF-a response to HBsAg was 22.0 (IQR: 6.5-65.0) and 106.50 (IQR: 58.5-203.0) spot-forming cells (SFC)/10 PBMC, respectively at week 0. The level of IFN-r secreted at weeks 12 and weeks 36 to 48 was comparable with that at week 0. However, IFN-r response was higher at weeks 12 than that at weeks 36 to 48 ( = 0.02). The level of TNF-a secreted at weeks 12 was higher than that at week 0 ( < 0.001). Total HIV DNA levels were 2.76 (IQR: 2.47-3.07), 2.77 (IQR: 2.50-3.09), 2.77 (IQR: 2.41-2.89) log copies/10 PBMCs at weeks 0, 12, 36 to 48, respectively. No correlation was observed between IFN-r and TNF-a levels and HBsAb titer as well as total HIV DNA levels after immunization.

CONCLUSION

Humoral immunity was satisfactory, but cellular immunity and decline in HIV reservoir were not optimal after HBV vaccine immunization in these patients.

摘要

背景

了解乙肝疫苗接种后的免疫反应对于预防艾滋病毒感染者的乙肝病毒感染以及实现成功治疗至关重要。

方法

在这项前瞻性研究中,32名CD4细胞计数>350个细胞/微升且HIV RNA<200拷贝/毫升的艾滋病毒感染者在第0、4和24周接种了20微克乙肝疫苗。我们在随访期间测量了总HIV DNA水平、乙肝表面抗体(HBsAb)滴度和乙肝表面抗原(HBsAg)特异性T细胞反应。

结果

所有患者免疫后均达到保护性HBsAb滴度。在第0周时,对HBsAg的干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)反应强度分别为22.0(四分位间距:6.5-65.0)和106.50(四分位间距:58.5-203.0)斑点形成细胞(SFC)/10个外周血单个核细胞(PBMC)。在第12周以及第36至48周时分泌的IFN-γ水平与第0周时相当。然而,第12周时的IFN-γ反应高于第36至48周时(P = 0.02)。第12周时分泌的TNF-α水平高于第0周时(P<0.001)。在第0、12、36至48周时,总HIV DNA水平分别为2.76(四分位间距:2.47-3.07)、2.77(四分位间距:2.50-3.09)、2.77(四分位间距:2.41-2.89)对数拷贝/10个PBMC。免疫后未观察到IFN-γ和TNF-α水平与HBsAb滴度以及总HIV DNA水平之间存在相关性。

结论

在这些患者中,乙肝疫苗免疫后的体液免疫令人满意,但细胞免疫和艾滋病毒储存库的下降并不理想。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/cca8ef1044d9/vaccines-11-00400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/6373b9b51bb0/vaccines-11-00400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/d546b118b6ce/vaccines-11-00400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/cca8ef1044d9/vaccines-11-00400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/6373b9b51bb0/vaccines-11-00400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/d546b118b6ce/vaccines-11-00400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80b1/9967144/cca8ef1044d9/vaccines-11-00400-g003.jpg

相似文献

1
Immune Responses to HBV Vaccine in People Living with HIV (PLWHs) Who Achieved Successful Treatment: A Prospective Cohort Study.对接受成功治疗的HIV感染者(PLWHs)的乙肝疫苗免疫反应:一项前瞻性队列研究。
Vaccines (Basel). 2023 Feb 9;11(2):400. doi: 10.3390/vaccines11020400.
2
Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course.人类免疫缺陷病毒感染者的乙型肝炎病毒疫苗接种:初次免疫疗程后长达7年的免疫原性及血清保护持久性
AIDS Res Hum Retroviruses. 2018 Nov;34(11):922-928. doi: 10.1089/AID.2017.0070. Epub 2018 Aug 16.
3
Immunogenicity of Sci-B-Vac (a Third-Generation Hepatitis B Vaccine) in HIV-Positive Adults.Sci-B-Vac(第三代乙肝疫苗)在HIV阳性成人中的免疫原性。
Isr Med Assoc J. 2017 Mar;19(3):143-146.
4
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.中国 HIV/HBV 合并感染患者治疗前后 HBV pgRNA 特征:一项多中心观察性队列研究。
J Viral Hepat. 2022 Aug;29(8):616-626. doi: 10.1111/jvh.13704. Epub 2022 Jun 7.
5
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.接种疫苗和中断抗逆转录病毒治疗后的HIV-1储存库动态与树突状细胞疫苗诱导的T细胞反应相关。
J Virol. 2015 Sep;89(18):9189-99. doi: 10.1128/JVI.01062-15. Epub 2015 Jun 24.
6
[Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].[重组乙型肝炎(rHB)疫苗及多形汉逊酵母细胞来源的乙肝表面抗原(HBsAg)的细胞免疫应答]
Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Jul;29(7):706-11.
7
Complementary Presence of HBV Humoral and T-cell Response Provides Protective Immunity after Neonatal Immunization.乙肝病毒体液免疫和T细胞反应的互补存在为新生儿免疫接种后提供保护性免疫。
J Clin Transl Hepatol. 2022 Aug 28;10(4):660-668. doi: 10.14218/JCTH.2021.00272. Epub 2022 Jan 4.
8
HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels.乙肝疫苗接种期间的HIV病毒血症会缩短保护性抗体水平的持续时间。
HIV Med. 2015 Mar;16(3):161-7. doi: 10.1111/hiv.12189. Epub 2015 Jan 14.
9
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.在 HBV 活跃的高效抗逆转录病毒治疗后,HIV-1-HBV 合并感染患者的乙型肝炎病毒(HBV)特异性 CD8+T 细胞没有增加。
J Virol. 2010 Mar;84(6):2657-65. doi: 10.1128/JVI.02124-09. Epub 2010 Jan 6.
10
Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.在卢旺达基加利,接受联合抗逆转录病毒疗法的 HIV 感染儿童和青少年中的乙型肝炎病毒流行情况和疫苗反应。
Pediatr Infect Dis J. 2013 Mar;32(3):246-51. doi: 10.1097/INF.0b013e318271b93d.

引用本文的文献

1
An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.一项高效的疫苗临床试验:美国国立过敏和传染病研究所艾滋病临床试验组A5379号针对HIV感染者的乙肝疫苗试验
Vaccine. 2025 May 10;55:127028. doi: 10.1016/j.vaccine.2025.127028. Epub 2025 Mar 26.
2
Immune response to GeneVac-B (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso.布基纳法索博博迪乌拉索地区按标准程序接种GeneVac-B(重组DNA注射用乙型肝炎疫苗)的人群的免疫反应。
IJID Reg. 2024 Nov 2;13:100483. doi: 10.1016/j.ijregi.2024.100483. eCollection 2024 Dec.
3
Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.

本文引用的文献

1
Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.长效卡博特韦-利匹韦林会成为所有艾滋病毒感染者的未来希望吗?基于意大利多中心队列基因型耐药性检测的回应
J Pers Med. 2022 Jan 31;12(2):188. doi: 10.3390/jpm12020188.
2
Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis.乙型肝炎病毒疫苗免疫反应在 HIV 感染者中的Meta 分析。
Front Immunol. 2021 Dec 22;12:745541. doi: 10.3389/fimmu.2021.745541. eCollection 2021.
3
Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study.
抗病毒药物和疫苗在孕妇中的安全性与有效性:基于生理的药代动力学建模及病毒感染动力学整合的见解
Vaccines (Basel). 2024 Jul 16;12(7):782. doi: 10.3390/vaccines12070782.
4
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.人类免疫缺陷病毒感染者接种疫苗的免疫原性和疗效
Viruses. 2023 Aug 30;15(9):1844. doi: 10.3390/v15091844.
HIV-1 DNA 衰减的治疗预测:一项多中心纵向队列研究。
BMC Infect Dis. 2021 Jun 22;21(1):592. doi: 10.1186/s12879-021-06267-5.
4
Naïve CD4 cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study.在因血液制品感染 HIV 的长期非进展者中,幼稚 CD4 细胞计数明显下降,高 HIV RNA 水平导致免疫进展:一项队列研究。
BMC Immunol. 2021 Jun 3;22(1):36. doi: 10.1186/s12865-021-00426-8.
5
Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?长期 TDF 联合 ART 治疗与 HIV-HBV 合并感染中 HBsAg 丢失的进展率——对功能性 HBV 治愈的启示?
J Acquir Immune Defic Syndr. 2020 Aug 15;84(5):527-533. doi: 10.1097/QAI.0000000000002386.
6
Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients.HIV感染患者双倍剂量乙肝疫苗接种免疫反应的系统评价与荟萃分析
Vaccine. 2020 May 19;38(24):3995-4000. doi: 10.1016/j.vaccine.2020.04.022. Epub 2020 Apr 23.
7
Shared immunotherapeutic approaches in HIV and hepatitis B virus: combine and conquer.在 HIV 和乙型肝炎病毒中共享免疫治疗方法:联合起来战胜疾病。
Curr Opin HIV AIDS. 2020 May;15(3):157-164. doi: 10.1097/COH.0000000000000621.
8
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.在开发长效注射剂以预防和治疗 HIV 的同时,应对全球乙型肝炎病毒负担。
Lancet HIV. 2020 Jun;7(6):e443-e448. doi: 10.1016/S2352-3018(19)30342-X. Epub 2019 Dec 20.
9
Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV.乙型肝炎疫苗接种和乙型肝炎免疫减弱在 HIV 感染者中的情况。
Curr HIV/AIDS Rep. 2019 Oct;16(5):395-403. doi: 10.1007/s11904-019-00461-6.
10
Two types of poor immunological responder showing distinct responses to long-term HAART.两种类型的免疫反应不良者对长期高效抗逆转录病毒治疗(HAART)表现出不同的反应。
Int J Infect Dis. 2019 Sep;86:178-187. doi: 10.1016/j.ijid.2019.07.037. Epub 2019 Aug 6.